Arbutus Biopharma Corporation $ABUS Shares Acquired by Two Seas Capital LP

Two Seas Capital LP boosted its holdings in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) by 14.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,589,158 shares of the biopharmaceutical company’s stock after purchasing an additional 1,597,897 shares during the period. Arbutus Biopharma makes up approximately 1.2% of Two Seas Capital LP’s holdings, making the stock its 11th biggest position. Two Seas Capital LP owned about 6.55% of Arbutus Biopharma worth $60,554,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ABUS. Goldman Sachs Group Inc. lifted its stake in Arbutus Biopharma by 290.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,075,948 shares of the biopharmaceutical company’s stock valued at $7,245,000 after purchasing an additional 1,544,070 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its stake in Arbutus Biopharma by 63.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 2,575,941 shares of the biopharmaceutical company’s stock valued at $7,960,000 after purchasing an additional 1,000,000 shares during the last quarter. Bank of America Corp DE lifted its stake in Arbutus Biopharma by 161.4% during the second quarter. Bank of America Corp DE now owns 1,197,655 shares of the biopharmaceutical company’s stock valued at $3,701,000 after purchasing an additional 739,429 shares during the last quarter. UBS Group AG lifted its stake in Arbutus Biopharma by 307.2% during the third quarter. UBS Group AG now owns 774,594 shares of the biopharmaceutical company’s stock valued at $3,517,000 after purchasing an additional 584,386 shares during the last quarter. Finally, Western Standard LLC acquired a new stake in Arbutus Biopharma during the third quarter valued at approximately $2,306,000. 43.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Wall Street Zen raised shares of Arbutus Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Arbutus Biopharma in a research report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $5.00.

Arbutus Biopharma Trading Down 2.3%

NASDAQ:ABUS opened at $4.25 on Friday. Arbutus Biopharma Corporation has a 1 year low of $3.04 and a 1 year high of $5.10. The firm’s fifty day simple moving average is $4.38 and its 200 day simple moving average is $4.41. The firm has a market capitalization of $839.55 million, a PE ratio of 5.12 and a beta of 0.63.

Arbutus Biopharma (NASDAQ:ABUS) last posted its earnings results on Tuesday, March 31st. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter. Arbutus Biopharma had a net margin of 83.95% and a return on equity of 129.32%. The business had revenue of $179.13 million for the quarter. As a group, analysts anticipate that Arbutus Biopharma Corporation will post -0.16 EPS for the current fiscal year.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.